Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
Author:
Publisher
Informa UK Limited
Subject
Oncology,Immunology,Immunology and Allergy
Link
https://tandfonline.com/doi/pdf/10.1080/2162402X.2015.1052212
Reference54 articles.
1. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
2. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
4. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
5. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Cited by 80 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The role of CRAF in cancer progression: from molecular mechanisms to precision therapies;Nature Reviews Cancer;2024-01-09
2. CD3ζ as a novel predictive biomarker of PD-1 inhibitor resistance in melanoma;Molecular and Cellular Probes;2023-12
3. Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?;Cancer and Metastasis Reviews;2023-04-06
4. MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance;Melanoma Research;2022-12-20
5. MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas;Proceedings of the National Academy of Sciences;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3